Development and emerging trends of drug resistance mutations in HIV: a bibliometric analysis based on CiteSpace

被引:2
作者
Chen, Xuannan [1 ]
Chen, Xi [2 ]
Lai, Yu [2 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Acupunture & Tuina Sch, Chengdu, Sichuan, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Sch Basic Med, Chengdu, Peoples R China
关键词
HIV; AIDS; drug resistance mutation; CiteSpace; bibliometric analysis; visualized analysis; hot research topics; 2ND-LINE ANTIRETROVIRAL THERAPY; TRANSFER INHIBITORS INSTIS; LOW-LEVEL VIREMIA; PROTEASE INHIBITORS; INFECTED CHILDREN; INTEGRASE; NAIVE; DOLUTEGRAVIR; EMERGENCE; REGIMENS;
D O I
10.3389/fmicb.2024.1374582
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background Antiretroviral therapy has led to AIDS being a chronic disease. Nevertheless, the presence of constantly emerging drug resistance mutations poses a challenge to clinical treatment. A systematic analysis to summarize the advancements and uncharted territory of drug resistance mutations is urgently needed and may provide new clues for solving this problem.Methods We gathered 3,694 publications on drug resistance mutations from the Web of Science Core Collection with CiteSpace software and performed an analysis to visualize the results and predict future new directions and emerging trends. Betweenness centrality, count, and burst value were taken as standards.Results The number of papers on HIV medication resistance mutations during the last 10 years shows a wave-like trend. In terms of nation, organization, and author, the United States (1449), University of London (193), and Mark A. Wainberg (66) are the most significant contributors. The most frequently cited article is "Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update." Hot topics in this field include "next-generation sequencing," "tenofovir alafenamide," "children," "regimens," "accumulation," "dolutegravir," "rilpivirine," "sex," "pretreatment drug resistance," and "open label." Research on drug resistance in teenagers, novel mutation detection techniques, and drug development is ongoing, and numerous publications have indicated the presence of mutations related to current medications. Therefore, testing must be performed regularly for patients who have used medications for a long period. Additionally, by choosing medications with a longer half-life, patients can take fewer doses of their prescription, increasing patient compliance.Conclusion This study involved a bibliometric visualization analysis of the literature on drug resistance mutations, providing insight into the field's evolution and emerging patterns and offering academics a resource to better understand HIV drug resistance mutations and contribute to the field's advancement.
引用
收藏
页数:17
相关论文
共 94 条
  • [1] Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients
    Aghokeng, Avelin F.
    Kouanfack, Charles
    Laurent, Christian
    Ebong, Eugenie
    Atem-Tambe, Arrah
    Butel, Christelle
    Montavon, Celine
    Mpoudi-Ngole, Eitel
    Delaporte, Eric
    Peeters, Martine
    [J]. AIDS, 2011, 25 (17) : 2183 - 2188
  • [2] Prevalence and Outcomes of Recycling NNRTIs Despite Documented NNRTI Resistance in HIV-Infected Children and Youth
    Agwu, Allison L.
    Chang, Jennifer Y.
    Wiegand, Ryan E.
    Wheeling, John T.
    Bohannon, Beverly A.
    Dominguez, Kenneth L.
    [J]. AIDS PATIENT CARE AND STDS, 2014, 28 (01) : 10 - 14
  • [3] Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis
    Ajose, Olawale
    Mookerjee, Siddharth
    Mills, Edward J.
    Boulle, Andrew
    Ford, Nathan
    [J]. AIDS, 2012, 26 (08) : 929 - 938
  • [4] High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence
    Anderson, Kim
    Pietersen, Elize
    Shepherd, Bryan E.
    Bian, Aihua
    Dheda, Keertan
    Warren, Robin
    Sterling, Timothy R.
    van der Heijden, Yuri F.
    [J]. HIV MEDICINE, 2022, 23 (10) : 1085 - 1097
  • [5] HIV drug resistance against strand transfer integrase inhibitors
    Anstett, Kaitlin
    Brenner, Bluma
    Mesplede, Thibault
    Wainberg, Mark A.
    [J]. RETROVIROLOGY, 2017, 14
  • [6] Antinori A, 2019, NEW MICROBIOL, V42, P69
  • [7] Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial
    Avihingsanon, Anchalee
    Hughes, Michael D.
    Salata, Robert
    Godfrey, Catherine
    McCarthy, Caitlyn
    Mugyenyi, Peter
    Hogg, Evelyn
    Gross, Robert
    Cardoso, Sandra W.
    Bukuru, Aggrey
    Makanga, Mumbi
    Badal-aesen, Sharlaa
    Mave, Vidya
    Ndege, Beatrice Wangari
    Fontain, Sandy Nerette
    Samaneka, Wadzanai
    Secours, Rode
    Van Schalkwyk, Marije
    Mngqibisa, Rosie
    Mohapi, Lerato
    Valencia, Javier
    Sugandhavesa, Patcharaphan
    Montalban, Esmelda
    Munyanga, Cornelius
    Chagomerana, Maganizo
    Santos, Breno R.
    Kumarasamy, Nagalingeswaran
    Kanyama, Cecilia
    Schooley, Robert T.
    Mellors, John W.
    Wallis, Carole L.
    Collier, Ann C.
    Grinsztejn, Beatriz
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 (06)
  • [8] Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations
    Avila-Rios, Santiago
    Parkin, Neil
    Swanstrom, Ronald
    Paredes, Roger
    Shafer, Robert
    Ji, Hezhao
    Kantor, Rami
    [J]. VIRUSES-BASEL, 2020, 12 (06):
  • [9] Low-level Viremia in Treated HIV-1 Infected Patients: Advances and Challenges
    Bai, Ruojing
    Lv, Shiyun
    Wu, Hao
    Dai, Lili
    [J]. CURRENT HIV RESEARCH, 2022, 20 (02) : 111 - 119
  • [10] Bayowa Joan Rokani, 2023, PLOS Glob Public Health, V3, pe0001020, DOI 10.1371/journal.pgph.0001020